Department of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan.
Int J Oncol. 2011 Feb;38(2):493-501. doi: 10.3892/ijo.2010.856. Epub 2010 Dec 3.
An anti-inflammatory enone fatty acid, (E)-9-oxooctadec-10-enoic acid (C10), was previously isolated from red alga (Gracilaria verrucosa). Of the many cellular signaling pathways activated in response to the inflammatory stimulus, lipopolysaccharide, the extracellular signal-regulated kinase 1/2, the stress-activated protein kinase/Jun N-terminal kinase and the nuclear factor-κB pathways were specifically blocked by C10 in the macrophage-like cell line, RAW264.7. In this study, we investigated the anti-angiogenic and anti-inflammatory activities of C10 in endothelial cells. C10 only partially inhibited the proliferation of human cancer cell lines at relatively high concentrations of over 20 μg/ml. However, C10 inhibited the proliferation of RAW264.7 cells and human umbilical vein endothelial cells (HUVECs) with half-maximal inhibitory concentration (IC50) values of 4-8 μg/ml. Both the proliferation and the migration of HUVECs induced by the vascular endothelial growth factor (VEGF) were markedly blocked by C10 with IC50 values of 2-3 μg/ml. The activation of nuclear factor of κ light polypeptide gene enhancer in B-cells inhibitor, α, by tumor necrosis factor-α or VEGF in these cells was also blocked by C10. Furthermore, in an in vivo model of angiogenesis in the mouse cornea, the neovascularization induced by VEGF was markedly inhibited by C10. The processes involved in inflammatory signaling, angiogenesis, and the development of malignancy in cancer are closely related, suggesting that C10 could be a useful lead compound for the development of novel anti-angiogenic therapies for cancer.
一种抗炎烯酮脂肪酸,(E)-9-氧代十八碳-10-烯酸(C10),先前从红藻(Gracilaria verrucosa)中分离得到。在许多对炎症刺激作出反应而激活的细胞信号通路中,脂多糖、细胞外信号调节激酶 1/2、应激激活蛋白激酶/Jun N-末端激酶和核因子-κB 通路在巨噬细胞样细胞系 RAW264.7 中被 C10 特异性阻断。在这项研究中,我们研究了 C10 在血管内皮细胞中的抗血管生成和抗炎活性。C10 仅在相对较高的浓度(超过 20 μg/ml)下才部分抑制人癌细胞系的增殖。然而,C10 以半最大抑制浓度(IC50)值为 4-8 μg/ml 抑制 RAW264.7 细胞和人脐静脉内皮细胞(HUVEC)的增殖。C10 以 2-3 μg/ml 的 IC50 值显著抑制由血管内皮生长因子(VEGF)诱导的 HUVEC 的增殖和迁移。肿瘤坏死因子-α或 VEGF 激活这些细胞中的核因子κ轻多肽基因增强子 B 细胞抑制剂-α(NF-κB)也被 C10 阻断。此外,在小鼠角膜血管生成的体内模型中,C10 显著抑制了 VEGF 诱导的新生血管形成。涉及炎症信号转导、血管生成和癌症恶性发展的过程密切相关,这表明 C10 可能是开发用于癌症的新型抗血管生成疗法的有用先导化合物。